Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $4.7MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Carver Kyle | Chief Financial Officer | Jul 08 '26 | Buy | $13.26 | 1,000 | $13,260 | 60,335 | Jul 10 07:59 PM |
| Kirsch Arthur S | Director | Jul 07 '26 | Buy | $13.30 | 10,000 | $133,000 | 10,000 | Jul 08 08:00 PM |
| Drew Janice Suzann | Chief of Dev. Operations | Jun 22 '26 | Option Exercise | $3.15 | 20,000 | $63,063 | 87,794 | Jun 24 08:00 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.